Literature DB >> 28275883

Elevated Plasma Homocysteine Level Increased the Risk of Early Renal Impairment in Acute Ischemic Stroke Patients.

Jingjuan Chen1, Guode Li1, Zuohang Xu1, Chengguo Zhang2, Yukai Wang1, Haiqun Xie1, Yan Shao1, Lingmei Peng1, Jiancong Lu1, Dahua Yuan1.   

Abstract

Renal insufficiency is associated with the prognosis of acute ischemic stroke (AIS) and homocysteine (Hcy) levels. This study investigated the association between plasma Hcy levels and renal insufficiency in patients with AIS. A total of 987 patients with AIS who had been treated at the First People's Hospital of Foshan between 2011 and 2014 were retrospectively studied. Based on their cystatin C (Cys C) levels, the patients were divided into the normal renal function group (Cys C ≤ 1.25 mg/L) or the renal impairment group (Cys C > 1.25 mg/L). Multivariate regression analysis was applied to reveal the association between hyperhomocysteinemia (HHcy) and renal impairment. The renal impairment group showed more advanced age of onset, higher percentage of prior stroke and hypertension, higher baseline National Institute of Health Stroke Scale score, lower high-density lipoprotein cholesterol levels, and higher Hcy levels compared with the normal renal function group. A multivariate analysis revealed a relationship between early renal impairment and Hcy levels: an increase of Hcy by 1 μmol/L was associated with an increase of 12-18% of the risk of renal impairment among patients with AIS and HHcy. Patients with AIS and HHcy had a 2.42-3.51 fold increase of the risk of renal impairment compared with patients with normal Hcy level (P < 0.001). In conclusion, patients with stroke and HHcy could be more prone to renal impairment.

Entities:  

Keywords:  Cystatin C; Glomerular filtration rate; Homocysteine; Renal insufficiency; Stroke

Mesh:

Substances:

Year:  2017        PMID: 28275883     DOI: 10.1007/s10571-017-0470-8

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  30 in total

Review 1.  Aetiology and treatment of hyperhomocysteinaemia causing ischaemic stroke.

Authors:  P K Sarkar; L A Lambert
Journal:  Int J Clin Pract       Date:  2001-05       Impact factor: 2.503

2.  Homocysteine and the risk of ischemic stroke in a triethnic cohort: the NOrthern MAnhattan Study.

Authors:  Ralph L Sacco; Kishlay Anand; Hye-Seung Lee; Bernadette Boden-Albala; Sally Stabler; Robert Allen; Myunghee C Paik
Journal:  Stroke       Date:  2004-09-02       Impact factor: 7.914

Review 3.  Homocysteine and cardiovascular disease.

Authors:  Dinesh K Kalra
Journal:  Curr Atheroscler Rep       Date:  2004-03       Impact factor: 5.113

Review 4.  Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease.

Authors:  M E Suliman; B Lindholm; P Bárány; J Bergström
Journal:  Clin Chem Lab Med       Date:  2001-08       Impact factor: 3.694

5.  Estimated GFR and risk of death--is cystatin C useful?

Authors:  Julie R Ingelfinger; Philip A Marsden
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

Review 6.  Homocysteine and cardiovascular disease: cause or effect?

Authors:  L Brattström; D E Wilcken
Journal:  Am J Clin Nutr       Date:  2000-08       Impact factor: 7.045

Review 7.  DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.

Authors:  Olaf Stanger; Wolfgang Herrmann; Klaus Pietrzik; Brian Fowler; Jürgen Geisel; Jutta Dierkes; Martin Weger
Journal:  Clin Chem Lab Med       Date:  2003-11       Impact factor: 3.694

8.  Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline.

Authors:  Ralph L Sacco; Robert Adams; Greg Albers; Mark J Alberts; Oscar Benavente; Karen Furie; Larry B Goldstein; Philip Gorelick; Jonathan Halperin; Robert Harbaugh; S Claiborne Johnston; Irene Katzan; Margaret Kelly-Hayes; Edgar J Kenton; Michael Marks; Lee H Schwamm; Thomas Tomsick
Journal:  Circulation       Date:  2006-03-14       Impact factor: 29.690

9.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Authors:  James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

10.  [Efficacy and safety of Enalapril-Folate acid tablets in lowering blood pressure and plasma homocysteine].

Authors:  Jian Ping Li; Yong Huo; Ping Liu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2007-12-18
View more
  2 in total

1.  Association between homocysteine, vitamin B 12 , folic acid and erectile dysfunction: a cross-sectional study in China.

Authors:  Yang Chen; Jie Li; Tianyu Li; Jianxiong Long; Jinling Liao; Gong-Hong Wei; Zengnan Mo; Jiwen Cheng
Journal:  BMJ Open       Date:  2019-05-22       Impact factor: 2.692

2.  Homocysteine is associated with higher risks of ischemic stroke: A systematic review and meta-analysis.

Authors:  Nícollas Nunes Rabelo; João Paulo Mota Telles; Leonardo Zumerkorn Pipek; Rafaela Farias Vidigal Nascimento; Rodrigo Coimbra de Gusmão; Manoel Jacobsen Teixeira; Eberval Gadelha Figueiredo
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.